Sb Technology Holdings, Inc. (VGLS) intrinsic value & 10-year financials

Sb Technology Holdings, Inc. (VGLS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to $347.8K, with an average return on invested capital of 779.0%.

Graham intrinsic value
—
Revenue (FY2014)
$347.8K
ROIC (10-yr avg)
779.0%
Free cash flow (FY2014)
-$23.7M

VGLS 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2014 $347.8K -$106.0M — -$23.7M -18940.6% 1467.9%
FY2013 $0 -$7.4M — — — 90.2%
FY2012 — — — — — —
FY1995 — — — — — —

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

SB Technology Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

SB Technology Holdings, Inc. has earned high returns on invested capital, averaging 52.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.

SB Technology Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

SB Technology Holdings, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.

VGLS stock: frequently asked questions

Does Sb Technology Holdings, Inc. generate free cash flow?

Sb Technology Holdings, Inc. generated -$23.7M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2014. Free cash flow was positive in 0 of the last 1 reported years.

What is VGLS's return on invested capital?

Average ROIC over the last 4 fiscal years was 779.0%, and average return on equity was 1266.4%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this VGLS data come from?

From Sb Technology Holdings, Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Nov 19, 2015. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks